Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03424122
Title INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Incyte Corporation
Indications

diffuse large B-cell lymphoma

follicular lymphoma

mantle cell lymphoma

marginal zone B-cell lymphoma

Therapies

Ibrutinib + Parsaclisib

Bendamustine + Parsaclisib + Rituximab

Parsaclisib + Rituximab

Age Groups: adult | senior
Covered Countries USA | ITA | ESP


No variant requirements are available.